Portal de Periódicos da CAPES

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

2019; American Medical Association; Volume: 5; Issue: 9 Linguagem: Inglês

10.1001/jamaoncol.2019.1022

2374-2445

Audrey Simonaggio, Jean‐Marie Michot, Anne Laure Voisin, Jérôme Le Pavec, Michael Collins, A. Lallart, Geoffray Cengizalp, Aurore Vozy, Ariane Laparra, Andréa Varga, Antoine Hollebecque, Stéphane Champiat, Aurélien Marabelle, Christophe Massard, Olivier Lambotte,

Colorectal Cancer Treatments and Studies

Although immune checkpoint inhibitors (ICIs), such as anti-PD-1 (programmed cell death 1) or anti-PD-L1 (programmed cell death 1 ligand 1), have proved effective in treating many cancers, patients receiving ICIs may experience immune-related adverse events (irAEs). Little evidence exists on the safety of resuming these treatments after an irAE.